CSV October 31, 2022 through October 31, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DIDANOSINE	ASSAY/	*USP41–NF36*	1275	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second*	Line 1 of *Guard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FOR ORAL SOLUTION	*Procedure/ Chromatographic system*						*Supplement to USP41–NF36*	*column*: Change 20-cm; to: 20-mm;
ISOSORBIDE DINITRATE SUBLINGUAL TABLETS	*Assay*	*USP41–NF36*	2272	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Change *Buffer solution*, *Mobile phase*, *Internal standard solution*, *Standard preparation*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Buffer solution*—Dissolve 15.4 g of ammonium acetate in water, add 11.5 mL of glacial acetic acid,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dilute with water to 1000 mL, and mix to obtain a solution having a pH of about 4.7. *Mobile phase*—Mix 350 mL of water, 100 mL of *Buffer solution*, and 550 mL of methanol. Cool to room temperature, dilute with water to 1000 mL, mix, degas, and filter. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Internal standard solution*—Transfer a quantity of diluted

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								nitroglycerin to a suitable volumetric flask, add about 60% of the flask volume of methanol, sonicate for 5 minutes, and shake for 30 minutes. Dilute with methanol to volume to obtain a solution having a concentration of about 3 mg of nitroglycerin per mL, and mix. Allow any undissolved material to settle, filter, and store the filtrate in an airtight container. *Standard prep aration* —Transfer about 125 mg of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								recently mixed USP Diluted Isosorbide Dinitrate RS, accurately weighed, to a 50-mL volumetric flask, add about 30 mL of *Mobile phase*, shake for 30 minutes, dilute with *Mobile phase* to volume, and mix. Pipet 10 mL of the resulting solution into a 25-mL volumetric flask, and add 4.0 mL of *Internal standard solution* and 4 mL of dilute *Buffer solution* (1 in 10). Cool to room temperature, dilute with

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Mobile phase to volume, and mix to obtain a solution having a known concentration of about 0.25 mg of isosorbide dinitrate per mL, based on the quantity of USP Diluted Isosorbide Dinitrate RS weighed and the labeled content of isosorbide dinitrate. Pass a portion of this solution through a 0.45-µm filter. AND Add *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								a 220-nm detector and a 4-mm × 25-cm column that contains packing L1. The flow rate is about 1 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between isosorbide dinitrate and nitroglycerin is not less than 2.0; and the relative standard deviation for replicate injections determined from the peak response ratios

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								is not more than 2%. [Note—The relative retention times are about 0.75 for isosorbide dinitrate and 1.0 for nitroglycerin. The relative retention times for isosorbide mononitrates, if present, are about 0.38.] AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Diluted Isosorbide Dinitrate*. to: Separately inject equal volumes (about 20 µL) of the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								preparation and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
REAGENTS	SOLUTIONS/*Volumetric Solutions*	*USP41–NF36*	5769	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1 of *0.1 N Potassium Hydroxide VS*: Change Transfer 100 mL of potassium hydroxide to a 1000-mL volumetric flask. to: Transfer 100 mL of *1 N Potassium Hydroxide VS* to a 1000-mL volumetric flask.
REPOSITORY CORTICOTROPIN INJECTION	ADDITIONAL REQUIREMENTS	*USP41–NF36*	1097	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	In *USP Reference Standards*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ISOSORBIDE DINITRATE CHEWABLE TABLETS	*Assay*	*USP41–NF36*	2270	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	<*11*>: Add USP Ascorbic Acid RS Change *Buffer solution, Mobile phase, Internal standard solution, Standard preparation,* and *Chromatographic system*—Prepare as directed in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Buffer solution*—Dissolve 15.4 g of ammonium acetate in water, add 11.5 mL of glacial acetic acid, dilute with water to 1000 mL, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mix to obtain a solution having a pH of about 4.7. *Mobile phase*—Mix 350 mL of water, 100 mL of *Buffer solution*, and 550 mL of methanol. Cool to room temperature, dilute with water to 1000 mL, mix, degas, and filter. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>.) *Internal standard solution*—Transfer a quantity of diluted nitroglycerin to a suitable

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								volumetric flask, add about 60% of the flask volume of methanol, sonicate for 5 minutes, and shake for 30 minutes. Dilute with methanol to volume to obtain a solution having a concentration of about 3 mg of nitroglycerin per mL, and mix. Allow any undissolved material to settle, filter, and store the filtrate in an airtight container. *Standard prep aration* —Transfer about 125 mg of recently mixed USP Diluted

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Isosorbide Dinitrate RS, accurately weighed, to a 50-mL volumetric flask, add about 30 mL of *Mobile phase*, shake for 30 minutes, dilute with *Mobile phase* to volume, and mix. Pipet 10 mL of the resulting solution into a 25-mL volumetric flask, and add 4.0 mL of *Internal standard solution* and 4 mL of dilute *Buffer solution* (1 in 10). Cool to room temperature, dilute with *Mobile phase* to volume, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mix to obtain a solution having a known concentration of about 0.25 mg of isosorbide dinitrate per mL, based on the quantity of USP Diluted Isosorbide Dinitrate RS weighed and the labeled content of isosorbide dinitrate. Pass a portion of this solution through a 0.45-µm filter. AND Add *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 220-nm detector and a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								4-mm × 25-cm column that contains packing L1. The flow rate is about 1 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between isosorbide dinitrate and nitroglycerin is not less than 2.0; and the relative standard deviation for replicate injections determined from the peak response ratios is not more than 2%. [Note—The

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								relative retention times are about 0.75 for isosorbide dinitrate and 1.0 for nitroglycerin. The relative retention times for isosorbide mononitrates, if present, are about 0.38.] AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Diluted Isosorbide Dinitrate*. to: Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
REAGENTS	REAGENT SPECIFICATIONS	*USP41–NF36*	5680	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1 of *Carbon Disulfide, CS*: Change Carbon Disulfide, CS to: Carbon Disulfide, CS_2
COLCHICINE	IM PURITIES/*Limit of Ethyl Acetate*/*System suitability*/*Suitability requirements*	*First Supplement to USP41–NF36*	8314	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Delete *Tailing factor*: NMT 2.0 for the menthol peak
ARGATROBAN	IM PURITIES/*Organic Impurities*	*USP41–NF36*	346	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Footnote b of *Table 2*: Change Ethyl (2*R*,4*R*)-1-[N^8-nitro-L-arginyl]-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								4-methylpiperidine-2-carboxylate hydrochloride. to: Ethyl (4*R*)-1-[N^8-nitro-L-arginyl]-4-methylpiperidine-2-carboxylate.
ISOSORBIDE DINITRATE TABLETS	*Assay*	*USP41–NF36*	2270	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Change *Buffer solution*, *Mobile phase*, *Internal standard solution*, *Standard preparation*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Buffer solution*—Dissolve 15.4 g of ammonium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								acetate in water, add 11.5 mL of glacial acetic acid, dilute with water to 1000 mL, and mix to obtain a solution having a pH of about 4.7. *Mobile phase*—Mix 350 mL of water, 100 mL of *Buffer solution*, and 550 mL of methanol. Cool to room temperature, dilute with water to 1000 mL, mix, degas, and filter. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Internal standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution—Transfer a quantity of diluted nitroglycerin to a suitable volumetric flask, add about 60% of the flask volume of methanol, sonicate for 5 minutes, and shake for 30 minutes. Dilute with methanol to volume to obtain a solution having a concentration of about 3 mg of nitroglycerin per mL, and mix. Allow any undissolved material to settle, filter, and store the filtrate in an airtight container. *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								prep aration—Transfer about 125 mg of recently mixed USP Diluted Isosorbide Dinitrate RS, accurately weighed, to a 50-mL volumetric flask, add about 30 mL of *Mobile phase*, shake for 30 minutes, dilute with *Mobile phase* to volume, and mix. Pipet 10 mL of the resulting solution into a 25-mL volumetric flask, and add 4.0 mL of *Internal standard solution* and 4 mL of dilute *Buffer solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(1 in 10). Cool to room temperature, dilute with *Mobile phase* to volume, and mix to obtain a solution having a known concentration of about 0.25 mg of isosorbide dinitrate per mL, based on the quantity of USP Diluted Isosorbide Dinitrate RS weighed and the labeled content of isosorbide dinitrate. Pass a portion of this solution through a 0.45-µm filter. AND Add *Chromatographic system* (see *Chromatograph*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								y <621>)—The liquid chromatograph is equipped with a 220-nm detector and a 4-mm × 25-cm column that contains packing L1. The flow rate is about 1 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between isosorbide dinitrate and nitroglycerin is not less than 2.0; and the relative standard deviation for replicate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								injections determined from the peak response ratios is not more than 2%. [Note—The relative retention times are about 0.75 for isosorbide dinitrate and 1.0 for nitroglycerin. The relative retention times for isosorbide mononitrates, if present, are about 0.38.] AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Diluted Isosorbide Dinitrate*. to: Separately

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
ZONISAMIDE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*USP41–NF36*	4410	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1 of *Apparatus 2*: Change 75 rpm, with sinkers (see *Dissolution* <711>, *Figure 2a*) to: 75 rpm. Use suitable sinkers, if necessary.
REAGENTS/INDICATORS AND SOLUTIONS	SOLUTIONS/*Volumetric*	*USP41–NF36*	5772	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	In the equation in *Standardization*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Solutions/0.01 M Sodium Thiosulfate VS							N = mg $K_2Cr_2O_7$/49.04 x mL $Na_2S_2O_3$ to: M = mg $K_2Cr_2O_7$/49.04 x mL $Na_2S_2O_3$
DESLORATADINE TABLETS	IMPURITIES	*USP41–NF36*	1178	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	*Organic Impurities*: Add Protect all solutions containing desloratadine from light.
ISOSORBIDE DINITRATE SUBLINGUAL TABLETS	*Identification*	*USP41–NF36*	2272	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1: Change Tablets respond to the *Identification* test under *Isosorbide Dinitrate Tablets*. to: Transfer a suitable quantity of finely powdered Tablets to a glass-stoppered centrifuge tube. Add 10 mL of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								sodium hydroxide solution (1 in 250), shake to wet the powder, then add 15 mL of solvent hexane, and again shake. Centrifuge the mixture, and transfer the upper phase to a beaker. Evaporate the solvent, and dry the residue in vacuum over anhydrous calcium chloride at room temperature for 16 hours: the IR absorption spectrum of a suitable solution in chloroform of the residue so obtained exhibits maxima only at the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								same wavelengths as that of a similar preparation from the residue obtained from USP Diluted Isosorbide Dinitrate RS.
HYDROGENATED VEGETABLE OIL	DEFINITION	*USP41–NF36*	5649	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2: Change The melting range, heavy metals limit, iodine value, and saponification value differ, to: The melting range, iodine value, and saponification value differ,
PEMETREXED FOR INJECTION	ASSAY/ *Procedure/Analysis*	*First Supplement to USP41–NF36*	Online	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 8 of the variable definition list: Change M_{r2} = molecular weight of pemetrexed disodium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(anhydrous), 473.37 to: M_{r2} = molecular weight of pemetrexed disodium (anhydrous), 471.38
SALMETEROL INHALATION POWDER	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP40–NF35*	6096	30-Mar-2018	1-Apr-2018	*USP42–NF37*	*USP42–NF37*	Line 2 of USP Salmeterol Related Compound H RS: Change 1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)benzyl]-2-naphthoic acid. $C_{36}H_{43}NO_6$ 585.73 to: 1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)benzyl]-2-naphthoic acid,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								monohydrate. $C_{36}H_{43}NO_6 \cdot H_2O$ 603.76
FLUTICASONE PROPIONATE AND SALMETEROL INHALATION POWDER	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP40–NF35*	4309	30-Mar-2018	1-Apr-2018	*USP42–NF37*	*USP42–NF37*	Line 2 of USP Salmeterol Related Compound H RS: Change 1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)benzyl]-2-naphthoic acid. $C_{36}H_{43}NO_6$ 585.73 to: 1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)benzyl]-2-naphthoic acid, monohydrate. $C_{36}H_{43}NO_6 \cdot H_2O$ 603.76
PLASTIC MATERIALS OF CONSTRU	TEST METHODS/*Tin in Non-Tin-*	*USP41–NF36*	6403	30-Mar-2018	1-Apr-2018	*USP42–NF37*	*USP42–NF37*	Line 3 of *Sample solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CTION	*Stabilized Materials*							Change If the solution is not colorless, add the sodium sulfate to: If the solution is not colorless, add the sodium sulfite
PERINDOPRIL ERBUMINE	IM PURITIES/*Limit of Perindopril Related Compound I*/*System suitability*	*USP40–NF35*	5644	30-Mar-2018	1-Apr-2018	*USP42–NF37*	*USP42–NF37*	Line 3: Add [Note—The relative retention times for perindopril and perindopril related compound I are 1.0 and 1.6, respectively.]
CHLORHEXIDINE GLUCONATE ORAL RINSE	*Identification*	*USP40–NF35*	3367	23-Feb-2018	1-Mar-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1 of *C*: Change Undiluted Oral Rinse used as the test solution meets the requirements for *Identification* test *B* under *Calcium Gluconate*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								except that a Standard solution containing about 0.6 mg of USP Potassium Gluconate RS per mL is used and 15 ?L of the test solution and the Standard solution are applied to the thin-layer chromatographic plate. to: Use undiluted Oral Rinse as the test solution and prepare a Standard solution of USP Potassium Gluconate RS in water containing 0.6 mg/mL. Apply separate 15-?L portions of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								test solution and the Standard solution to a suitable thin-layer chromatographic plate (see *Chromatography* <621>) coated with a 0.25-mm layer of chromatographic silica gel, and allow to dry. Develop the chromatogram in a solvent system consisting of a mixture of alcohol, water, ammonium hydroxide, and ethyl acetate (50:30:10:10) until the solvent front has moved about three-fourths of the length of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								plate. Remove the plate from the chamber, and dry at 110° for 20 minutes. Allow to cool and spray with a spray reagent prepared as follows. Dissolve 2.5 g of ammonium molybdate in about 50 mL of 2 N sulfuric acid in a 100-mL volumetric flask, add 1.0 g of ceric sulfate, swirl to dissolve, dilute with 2 N sulfuric acid to volume, and mix. Heat the plate at 110° for about 10 minutes: the principal spot obtained from the test solution corresponds in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								color, size, and R_F value to that obtained from the Standard solution.
REAGENTS	REAGENT SPECIFICATIONS	*USP41–NF36*	5724	23-Feb-2018	1-Mar-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2 of *9Z-Retinoic Acid*: Change *Acidalitretinoin)*, to: *Alitretinoin)*,
AMLODIPINE AND ATORVASTATIN TABLETS	IMPURITIES/*Organic Impurities Related to Atorvastatin*	*First Supplement to USP41–NF36*	8270	23-Feb-2018	1-Mar-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	In the variable definition list in *Analysis*: Change M_{r2} = molecular weight of atorvastatin calcium, 1209.39 to: M_{r2} = molecular weight of atorvastatin calcium, 1155.34
PIPERACILLIN AND TAZOBACTAM FOR INJECTION	IMPURITIES/*Organic Impurities, Procedure*	*USP40–NF35*	5728	23-Feb-2018	1-Mar-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Footnote m: Change (2*S*,5*R*,6*R*)-Ethyl 6-((*R*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	2/Table 3							)-2-{(2*S*,5*R*,6*R*)-6-[(*R*)-2-(4-ethyl-2,3-dioxopiperazine-1-carboxamido)-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxamido}-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate. to: 2-(((3-Acetyl-4-(ethoxycarbonyl)-5,5-dimethylthiazolidin-2-yl)methyl)amino)-2-oxo-1-phenylethyl 6-(2-(4-ethyl-2,3-dioxopiperazine-1-carboxamido)-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								3.2.0]heptane-2-carboxylate.
AMLODIPINE AND ATORVASTATIN TABLETS	ASSAY/*Procedure*	*First Supplement to USP41–NF36*	8270	23-Feb-2018	1-Mar-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	In the variable definition list of the second equation in *Analysis*: Change M_{r2} = molecular weight of atorvastatin calcium, 1209.39 to: M_{r2} = molecular weight of atorvastatin calcium, 1155.34
NOREPINEPHRINE BITARTRATE	IDENTIFICATION/*B. Procedure*	*USP40–NF35*	5380	23-Feb-2018	1-Mar-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1 of *Analysis*: Change Add 1 drop of ferric chloride TS. to: Add 1 drop of ferric chloride TS to 2 mL of *Sample solution*.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
INHALATION AND NASAL DRUG PRODUCTS: AEROSOLS, SPRAYS, AND POWDERS—PERFORMANCE QUALITY TESTS	C. AERODYNAMIC SIZE DISTRIBUTION—INHALATION AEROSOLS, SPRAYS, AND POWDERS	*USP41–NF36*	6327	23-Feb-2018	1-Mar-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	*Figure 6*: Change Boquilla del Inhalador to: Inhaler Mouthpiece AND Change Tubo de Admisión to: Induction Port AND Change Cono de Ingreso to: Entrance Cone
ANTIBIOTICS—MICROBIAL ASSAYS	CALCULATIONS/*Turbidimetric Assay*/*Sample Data*	*USP40–NF35*	143	23-Feb-2018	1-Mar-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Second equation in *Step 1*: Change 0.0125 = to: 0.0062 = AND Third equation in *Step 1*: Change 0.0325 = to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PAROXETINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP40–NF35*	Online	23-Feb-2018	1-Mar-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	0.0322 = Line 1 of USP Paroxetine Related Compound F RS: Change *trans* (?)-1-Methyl-3-[1,3-benzodioxol-5-yloxy)methyl]-4-(fluorophenyl)piperidine. to: (3*S*,4*R*)-3-[(Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-methylpiperidine.
AMLODIPINE AND ATORVASTATIN TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*First Supplement to USP41–NF36*	8270	23-Feb-2018	1-Mar-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	In the variable definition list of the second equation in *Analysis*: Change M_{r2} = molecular weight of atorvastatin calcium, 1209.39 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								M_{r2} = molecular weight of atorvastatin calcium, 1155.34
NOREPINEPHRINE BITARTRATE	ASSAY/ *Procedure*	*USP40–NF35*	5380	23-Feb-2018	1-Mar-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1 of *Sample solution*: Change 25 mg/mL of Norepinephrine Bitartrate in glacial acetic acid. If necessary warm slightly to effect solution. to: Dissolve 500 mg of Norepinephrine Bitartrate in 20 mL of glacial acetic acid, warming slightly if necessary to effect solution.
STATISTICAL TOOLS FOR PROCEDURE VALIDATION	3. ACCURACY AND PRECISION/*3.1 Methods for*	*USP41–NF36*	7622	23-Feb-2018	1-Mar-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Paragraph 4: Change For example, with ? = 0.05

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Estimating Accuracy and Precision							and $n = 9$, $t_{0.95:8} = 1.860$ provides a 100(1? 2 × 1.05)% to: For example, with ? = 0.05 and $n = 9$, $t_{0.95:8} = 1.860$ provides a 100(1 ? 2 × 0.05)%
POWDERED ECHINACEA PALLIDA EXTRACT	IDENTIFICATION	*USP40–NF35*	6935	26-Jan-2018	1-Feb-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 5 of *A. Thin-Layer Chromatography/Presence of echinacoside and absence of dicaffeoylquinic acid*/*System suitability*: Change *Standard solution B* shows two major blue bands at about the middle of the chromatogram

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								due to caftaric acid (lower R_F) and chlorogenic acid (higher R_F) that are clearly separated, to: *Standard solution B* shows two major blue bands at about the middle of the chromatogram due to caftaric acid (higher R_F) and chlorogenic acid (lower R_F) that are clearly separated, AND Lines 3 and 6 of *C.*: Change *Standard solution B,* to: *Standard solution C,* AND Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard solution C) to: *Standard solution D*)
PHENYTOIN ORAL SUSPENSION	PERFORMANCE TESTS/ *Dissolution <711>*	*USP41–NF36*	3286	26-Jan-2018	1-Feb-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	In the *Analysis*: Change C_S = concentration of USP Phenytoin RS in the *Standard solution* to: C_S = concentration of USP Phenytoin RS in the *Standard solution* (mg/mL)
ESZOPICLONE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Revision Bulletin (Official August 01, 2017)*	Online	26-Jan-2018	1-Feb-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2 of USP Eszopiclone Related Compound A RS: Change 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyr

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								rolo[3,4-*b*]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide. $C_{17}H_{17}ClN_6O_4$ 404.81 to: [Note—This material may be available in the free base or salt form.] 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide. $C_{17}H_{17}ClN_6O_4$ 404.81 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-*b*]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide, 3-chlorobenzoic salt (1:1). $C_{17}H_{17}ClN_6O_4 \cdot C_7H_5ClO$ 561.38
POWDERED DIGITALIS	IDENTIFICATION/*B. Thin-Layer Chromatographic Identification Test*	*USP40–NF35*	3762	26-Jan-2018	1-Feb-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 3 of *Standard solution A*: Change lead acetate, to: lead acetate TS, AND Line 11 of *Analysis*: Change Locate the two prominent bands from *Standard solution A* corresponding in R_F value to the two bands from *Standard solution B*. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Locate the prominent bands from *Standard solution A* corresponding in R_F value to the band from *Standard solution B*.
NEVIRAPINE TABLETS	IMPURITIES/*Organic Impurities*	*USP40–NF35*	5333	26-Jan-2018	1-Feb-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1 of *Standard solution*: Change 0.125 ?g/mL of USP Nevirapine Anhydrous RS from *Standard stock solution A* in *Diluent* to: 0.125 ?g/mL of USP Nevirapine Anhydrous RS in *Diluent*
ECHINACEA PALLIDA	IDENTIFICATION	*USP40–NF35*	6931	26-Jan-2018	1-Feb-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 5 of *A. Thin-Layer Chromatography/Presence of echinacoside and absence of*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dicaffeoylquinic acid/*System suitability*: Change *Standard solution B* shows two major blue bands at about the middle of the chromatogram due to caftaric acid (lower R_F) and chlorogenic acid (higher R_F) that are clearly separated, to: *Standard solution B* shows two major blue bands at about the middle of the chromatogram due to caftaric acid (higher R_F) and chlorogenic acid (lower *R*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								F) that are clearly separated, AND Lines 3 and 6 of *C.*: Change *Standard solution B,* to: *Standard solution C,* AND Change *Standard solution C*) to: *Standard solution D*)
POWDERED ECHINACEA PURPUREA	IDENTIFICATION	*USP40–NF35*	6942	26-Jan-2018	1-Feb-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 3 of *A. Thin-Layer Chromatography/ Presence of chicoric acid and absence of echinacoside/System suitability*: Change *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution B shows two major blue bands at about the middle of the chromatogram due to caftaric acid (lower R_F) and chlorogenic acid (higher R_F) that are clearly separated, to: *Standard solution B* shows two major blue bands at about the middle of the chromatogram due to caftaric acid (higher R_F) and chlorogenic acid (lower R_F) that are clearly separated,
ECHINACEA SPECIES POWDER	IDENTIFICATION	*USP41–NF36*	4595	26-Jan-2018	1-Feb-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 4 of *A. HPTLC for Articles of*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CAPSULES								*Botanical Origin <203>*/*For Capsules containing Echinacea angustifolia powder prepared from dried rhizome and roots*/*System suitability*: Change *Standard solution B* shows two major blue bands at about the middle section due to caftaric acid (lower R_F) and chlorogenic acid (higher R_F) that are clearly separated, to: *Standard solution B* shows two major blue

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								bands at about the middle section due to caftaric acid (higher R_F) and chlorogenic acid (lower R_F) that are clearly separated,
TIMOLOL MALEATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP40–NF35*	8416	26-Jan-2018	1-Feb-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2 of USP Timolol Related Compound A RS: Change (*R*)-1-(*tert*-Butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-2-ol. $C_{13}H_{24}N_4O_3S$ 316.42 to: (*R*)-1-(*tert*-Butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-2-ol maleate. $C_{13}H_{24}N_4O_3S \cdot C$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_{4}H_4O_4$ 432.49 AND Line 2 of USP Timolol Related Compound C RS: Change *N*-(*tert*-Butyl)-2,3-bis(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-1-amine. $C_{19}H_{31}N_7O_4S_2$ 485.19 to: *N*-(*tert*-Butyl)-2,3-bis(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-1-amine maleate. $C_{19}H_{31}N_7O_4S_2$? $C_4H_4O_4$ 601.69 AND Line 3 of USP Timolol Related Compound D RS: Change $C_6H_9N_7O_4S$ to: $C_6H_9N_3O_2S$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Line 2 of USP Timolol Related Compound E RS: Change (*S*)-3-(*tert*-Butylamino)-1-(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-2-yl hydrogen maleate. $C_{17}H_{26}N_4O_6S$ 414.48 to: (*S*,*Z*)-4-({1-(*tert*-Butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]propan-2-yl}oxy)-4-oxobut-2-enoic acid maleate salt (1:1) $C_{17}H_{26}N_4O_6S$? $C_4H_4O_4$ 530.55
IMMUNOLOGICAL TEST METHODS—ENZYM	*USP40–NF35*	1344		26-Jan-2018	1-Feb-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 7 of *Coating the Solid Phase—Im*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
E-LINKED IMMUNOSORBENT ASSAY (ELISA)								*mobilization of Capture Reagent*: Change 1–10 µg/well to: 1–10 µg/mL
ESZOPICLONE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP40–NF35*	4090	26-Jan-2018	1-Feb-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2 of USP Eszopiclone Related Compound A RS: Change 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide. $C_{17}H_{17}ClN_6O_4$ 404.81 to: [Note—This material may be available in the free base or salt form.] 6-(5-Chloropyrid

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								in-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide. $C_{17}H_{17}ClN_6O_4$ 404.81 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide, 3-chlorobenzoic salt (1:1). $C_{17}H_{17}ClN_6O_4 \cdot C_7H_5ClO$ 561.38
POWDERED ECHINACEA ANGUSTIFOLIA	IDENTIFICATION	*USP40–NF35*	6926	26-Jan-2018	1-Feb-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 5 of *A. Thin-Layer Chromatography/Presence of echinacoside and*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dicaffeoylquinic acid/*System suitability*: Change *Standard solution B* shows two major blue bands at about the middle of the chromatogram due to caftaric acid (lower R_F) and chlorogenic acid (higher R_F) that are clearly separated, to: *Standard solution B* shows two major blue bands at about the middle of the chromatogram due to caftaric acid (higher R_F) and chlorogenic acid (lower *R*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								F) that are clearly separated, AND Line 3 of *C*.: Change *Standard solution B*, to: *Standard solution C*,
ECHINACEA PURPUREA AERIAL PARTS	IDENTIFICATION	*USP40–NF35*	6937	26-Jan-2018	1-Feb-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 3 of *A. Thin-Layer Chromatography/ Presence of chicoric acid and absence of echinacoside/System suitability*: Change *Standard solution B* shows two major blue bands at about the middle of the chromatogram

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								due to caftaric acid (lower R_F) that are clearly separated, to: *Standard solution B* shows two major blue bands at about the middle of the chromatogram due to caftaric acid (higher R_F) and chlorogenic acid (lower R_F) that are clearly separated,
ECHINACEA SPECIES DRY EXTRACT CAPSULES	IDENTIFICATION	*USP41–NF36*	4590	26-Jan-2018	1-Feb-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 4 of *A. HPTLC for Articles of Botanical Origin <203>/For Capsules containing Echinacea angustifolia Dry Extract/System suitability*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard solution B shows two major blue bands at about the middle section due to caftaric acid (lower R_F) and chlorogenic acid (higher R_F) that are clearly separated, to: *Standard solution B* shows two major blue bands at about the middle section due to caftaric acid (higher R_F) and chlorogenic acid (lower R_F) that are clearly separated,
QUETIAPINE EXTENDED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*	*Revision Bulletin (Official November 01, 2017)*	Online	26-Jan-2018	1-Feb-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Footnote a of *Table 5*: Change total impurities.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: total degradation products. AND Footnote b: Change total impurities. to: total degradation products.
DOBUTAMINE IN DEXTROSE INJECTION	*Identification*	*USP40–NF35*	3843	26-Jan-2018	1-Feb-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1 of *B*: Change It meets the requirements for the *Identification* test under *Dextrose*. to: Add a few drops of a solution (1 in 20) to 5 mL of hot alkaline cupric tartrate TS. A copious red precipitate of cuprous oxide is formed.
TIMOLOL	ADDITIONAL R	*USP40–NF35*	6481	26-Jan-2018	1-Feb-2018	*USP42–NF37*	*Second*	Line 3 of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MALEATE TABLETS	EQUIREMENTS/*USP Reference Standards <11>*						*Supplement to USP41–NF36*	Timolol Related Compound D RS: Change $C_6H_9N_7O_4S$ to: $C_6H_9N_3O_2S$
POWDERED ECHINACEA PALLIDA	IDENTIFICATION	*USP40–NF35*	6933	26-Jan-2018	1-Feb-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 5 of *A. Thin-Layer Chromatography/Presence of echinacoside and absence of dicaffeoylquinic acid/System suitability*: Change *Standard solution B* shows two major blue bands at about the middle of the chromatogram due to caftaric acid (lower R_F) and chlorogenic acid (higher R_F) that are clearly separated, to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard solution B shows two major blue bands at about the middle of the chromatogram due to caftaric acid (higher R_F) and chlorogenic acid (lower R_F) that are clearly separated, AND Lines 3 and 6 of *C.*: Change *Standard solution B,* to: *Standard solution C,* AND Change *Standard solution C*) to: *Standard solution D*)
POWDERED ECHINACEA	IDENTIFICATION	*USP40–NF35*	6944	26-Jan-2018	1-Feb-2018	*USP42–NF37*	*Second Supplement to*	Line 3 of *A. Thin-Layer Chro*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PURPUREA EXTRACT							*USP41–NF36*	*matography/Presence of chicoric acid and absence of echinacoside/System suitability*: Change *Standard solution B* shows two major blue bands at about the middle of the chromatogram due to caftaric acid (lower R_F) and chlorogenic acid (higher R_F) that are clearly separated, to: *Standard solution B* shows two major blue bands at about the middle of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								chromatogram due to caftaric acid (higher R_F) and chlorogenic acid (lower R_F) that are clearly separated,

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 16
- Page 17
- Page 18
- Page 19
- Page 20
- Page 21
- Page 22
- Page 23
- Page 24
- …
- Next page Next ›
- Last page Last »